| dbo:abstract
|
- Pipamazine (INN; trade names Mornidine, Mometine, Nausidol) is a drug of the phenothiazine class formerly used as an antiemetic. It is chemically related to chlorpromazine, but has negligible antipsychotic activity and produces few extrapyramidal side effects. Pipamazine was introduced to the U.S. market in 1959 by G. D. Searle & Company. It was advertised for morning sickness and postoperative nausea and vomiting, and was claimed to reduce the need for postoperative analgesia.It was eventually withdrawn from the U.S. market in 1969, after reports of hepatotoxicity (liver injury). There is very little published information on pipamazine; it is mostly absent from modern-day sources, apart from a few passing mentions in the pharmacological literature. (en)
|
| dbo:casNumber
| |
| dbo:chEBI
| |
| dbo:chEMBL
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 5894 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:alt
|
- Chemical structure of Pipamazine (en)
|
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chebi
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:cl
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalStatus
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyCategory
|
- Formerly used for morning sickness (en)
|
| dbp:pubchem
| |
| dbp:routesOfAdministration
|
- Oral, intramuscular injection (en)
|
| dbp:s
| |
| dbp:smiles
|
- C1CNCCCN2C3=CC=CC=C3SC4=C2C=CCl (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- OSJJYEUEJRVVOD-UHFFFAOYSA-N (en)
|
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Pipamazine (INN; trade names Mornidine, Mometine, Nausidol) is a drug of the phenothiazine class formerly used as an antiemetic. It is chemically related to chlorpromazine, but has negligible antipsychotic activity and produces few extrapyramidal side effects. Pipamazine was introduced to the U.S. market in 1959 by G. D. Searle & Company. It was advertised for morning sickness and postoperative nausea and vomiting, and was claimed to reduce the need for postoperative analgesia.It was eventually withdrawn from the U.S. market in 1969, after reports of hepatotoxicity (liver injury). (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
